Literature DB >> 27001822

Successful Salvage of Central Venous Catheters in Patients with Catheter-Related or Central Line-Associated Bloodstream Infections by Using a Catheter Lock Solution Consisting of Minocycline, EDTA, and 25% Ethanol.

Issam Raad1, Anne-Marie Chaftari2, Ramia Zakhour2, Mary Jordan2, Zanaib Al Hamal2, Ying Jiang2, Ammar Yousif2, Kumait Garoge2, Victor Mulanovich2, George M Viola2, Soha Kanj2, Egbert Pravinkumar2, Joel Rosenblatt2, Ray Hachem2.   

Abstract

In cancer patients with long-term central venous catheters (CVC), removal and reinsertion of a new CVC at a different site might be difficult because of the unavailability of accessible vascular sites. In vitro and animal studies showed that a minocycline-EDTA-ethanol (M-EDTA-EtOH) lock solution may eradicate microbial organisms in biofilms, hence enabling the treatment of central line-associated bloodstream infections (CLABSI) while retaining the catheter in situ Between April 2013 and July 2014, we enrolled 30 patients with CLABSI in a prospective study and compared them to a historical group of 60 patients with CLABSI who had their CVC removed and a new CVC inserted. Each catheter lumen was locked with an M-EDTA-EtOH solution for 2 h administered once daily, for a total of 7 doses. Patients who received locks had clinical characteristics that were comparable to those of the control group. The times to fever resolution and microbiological eradication were similar in the two groups. Patients with the lock intervention received a shorter duration of systemic antibiotic therapy than that of the control patients (median, 11 days versus 16 days, respectively; P < 0.0001), and they were able to retain their CVCs for a median of 74 days after the onset of bacteremia. The M-EDTA-EtOH lock was associated with a significantly decreased rate of mechanical and infectious complications compared to that of the CVC removal/reinsertion group, who received a longer duration of systemic antimicrobial therapy. (This study has been registered at ClinicalTrials.gov under registration no. NCT01539343.).
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27001822      PMCID: PMC4879419          DOI: 10.1128/AAC.02565-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  EDTA, the traditional anticoagulant of haematology: with increased automation is it time for a review?

Authors:  D M Reardon; B Warner; E A Trowbridge
Journal:  Med Lab Sci       Date:  1991-01

Review 2.  Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system.

Authors:  Eyal Zimlichman; Daniel Henderson; Orly Tamir; Calvin Franz; Peter Song; Cyrus K Yamin; Carol Keohane; Charles R Denham; David W Bates
Journal:  JAMA Intern Med       Date:  2013 Dec 9-23       Impact factor: 21.873

3.  Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm.

Authors:  Issam I Raad; Hend A Hanna; Maha Boktour; Gassan Chaiban; Ray Y Hachem; Tanya Dvorak; Russell Lewis; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement.

Authors:  I Raad; W Costerton; U Sabharwal; M Sacilowski; E Anaissie; G P Bodey
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

5.  Efficacy of minocycline and EDTA lock solution in preventing catheter-related bacteremia, septic phlebitis, and endocarditis in rabbits.

Authors:  Issam Raad; Ray Hachem; Robert K Tcholakian; Robert Sherertz
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study.

Authors:  Nuria Fernandez-Hidalgo; Benito Almirante; Raquel Calleja; Isabel Ruiz; Ana M Planes; Dolors Rodriguez; Carles Pigrau; Albert Pahissa
Journal:  J Antimicrob Chemother       Date:  2006-04-05       Impact factor: 5.790

7.  Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality.

Authors:  D Pittet; D Tarara; R P Wenzel
Journal:  JAMA       Date:  1994-05-25       Impact factor: 56.272

8.  Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial.

Authors:  Lennert Slobbe; Jeanette K Doorduijn; Pieternella J Lugtenburg; Abdelilah El Barzouhi; Eric Boersma; Willem B van Leeuwen; Bart J A Rijnders
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

9.  Chelator-based catheter lock solutions in eradicating organisms in biofilm.

Authors:  I Raad; J Rosenblatt; R Reitzel; Y Jiang; T Dvorak; R Hachem
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

10.  Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse.

Authors:  Hend Hanna; Claude Afif; Badie Alakech; Maha Boktour; Jeffrey Tarrand; Ray Hachem; Issam Raad
Journal:  Infect Control Hosp Epidemiol       Date:  2004-08       Impact factor: 3.254

View more
  8 in total

Review 1.  Targeting microbial biofilms: current and prospective therapeutic strategies.

Authors:  Hyun Koo; Raymond N Allan; Robert P Howlin; Paul Stoodley; Luanne Hall-Stoodley
Journal:  Nat Rev Microbiol       Date:  2017-09-25       Impact factor: 60.633

2.  Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria.

Authors:  Maristela P Freire; Ligia C Pierrotti; Antonio E Zerati; Luciana Benites; Joaquim Mauricio da Motta-Leal Filho; Karim Y Ibrahim; Pedro H Araujo; Edson Abdala
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 3.  Novel Treatment Strategies for Biofilm-Based Infections.

Authors:  Claudia Vuotto; Gianfranco Donelli
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

4.  In Vitro Assessment of the Antimicrobial Efficacy of Optimized Nitroglycerin-Citrate-Ethanol as a Nonantibiotic, Antimicrobial Catheter Lock Solution for Prevention of Central Line-Associated Bloodstream Infections.

Authors:  Ruth A Reitzel; Joel Rosenblatt; Cheryl Hirsh-Ginsberg; Kimberly Murray; Anne-Marie Chaftari; Ray Hachem; Issam Raad
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

5.  S-Nitroso-N-acetyl-l-cysteine Ethyl Ester (SNACET) Catheter Lock Solution to Reduce Catheter-Associated Infections.

Authors:  Rajnish Kumar; Hamed Massoumi; Manjyot Kaur Chug; Elizabeth J Brisbois
Journal:  ACS Appl Mater Interfaces       Date:  2021-05-24       Impact factor: 10.383

6.  Nephrologists Hate the Dialysis Catheters: A Systemic Review of Dialysis Catheter Associated Infective Endocarditis.

Authors:  Kalyana C Janga; Ankur Sinha; Sheldon Greenberg; Kavita Sharma
Journal:  Case Rep Nephrol       Date:  2017-03-20

Review 7.  Antimicrobial Locks in Patients Receiving Home Parenteral Nutrition.

Authors:  Dane Christina Daoud; Geert Wanten; Francisca Joly
Journal:  Nutrients       Date:  2020-02-10       Impact factor: 5.717

8.  Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  Boris Böll; Enrico Schalk; Dieter Buchheidt; Justin Hasenkamp; Michael Kiehl; Til Ramon Kiderlen; Matthias Kochanek; Michael Koldehoff; Philippe Kostrewa; Annika Y Claßen; Sibylle C Mellinghoff; Bernd Metzner; Olaf Penack; Markus Ruhnke; Maria J G T Vehreschild; Florian Weissinger; Hans-Heinrich Wolf; Meinolf Karthaus; Marcus Hentrich
Journal:  Ann Hematol       Date:  2020-09-30       Impact factor: 3.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.